Skip to main
TEVA

Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical (TEVA) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Teva Pharmaceutical Industries demonstrates a solid growth trajectory, evidenced by projected sales increases for key products such as Ajovy and Uzedy, with forecasts of $785 million and $278 million respectively by 2026, reflecting respective year-over-year growth rates of 17% and 45%. The company's successful strategic focus on higher-value products is expected to enhance EBITDA margins, with a strong anticipated cash flow expansion by 2027, bolstered by substantial cost savings of $700 million. With significant market share opportunities in high-demand therapeutic areas and ongoing sales growth in established products like Austedo, Teva is poised for continued financial resilience and growth in the coming years.

Bears say

Teva Pharmaceutical Industries faces a challenging financial outlook due to expected sequential declines in Q1 2026 sales resulting from inventory patterns and a Year-over-Year decrease anticipated in Q4 2026 due to pricing pressures leading up to Inflation Reduction Act (IRA) implementation. Additionally, while Austedo sales are projected to rise in 2026, a downturn is expected in 2027, reflecting potential volatility in their revenue streams, especially within their generics division, which reported revenues that missed estimates by 3% due to a significant Year-over-Year decline in US prescriptions. Furthermore, regulatory uncertainties surrounding tariffs and Most-Favored-Nation policies, along with challenges in litigation and pipeline execution, pose additional risks that could hinder Teva's financial recovery and operational stability.

Teva Pharmaceutical (TEVA) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teva Pharmaceutical (TEVA) Forecast

Analysts have given Teva Pharmaceutical (TEVA) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Teva Pharmaceutical (TEVA) has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teva Pharmaceutical (TEVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.